skip to Main Content

Study Uses Precision Medicine to Speed Drug Testing for Pancreatic Cancer

Newsfeed image, light gray text on dark gray background
Pancreatic cancer is among the world’s toughest cancers, with a five-year survival rate of just 10 percent. Effective treatments for pancreatic cancer are limited and the National Comprehensive Cancer Network’s guidelines point to clinical trials as the best option for treatment.

Fortunately, Moores Cancer Center at UC San Diego Health is among the few clinical trial sites in the U.S. for the Pancreatic Cancer Action Network’s (PanCAN) newly created Precision Promise, the first large-scale precision medicine trial designed to transform outcomes for patients with pancreatic cancer. Read more . . .


Back To Top